Clasificación actual del cáncer de mamaImplicación en el tratamiento y pronóstico de la enfermedad

  1. Miriam Alcaide Lucena 1
  2. Carlos José Rodríguez González 2
  3. Saturnino de Reyes Lartategui 1
  4. Tania Gallart Aragón 1
  5. María Teresa Sánchez Barrón 1
  6. Jesús García Rubio 1
  7. Pablo Juan Torne Poyatos 1
  1. 1 Unidad de Patología Mamaria. Servicio de Cirugía General y Aparato Digestivo. Hospital Universitario San Cecilio. Granada.
  2. 2 Unidad de Patología Mamaria. Servicio de Oncología Médica Hospital Universitario San Cecilio. Granada.
Revue:
Cirugía Andaluza

ISSN: 2695-3811,  1130-3212

Année de publication: 2021

Volumen: 32

Número: 2

Pages: 155-159

Type: Article

DOI: 10.37351/2021322.9 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

D'autres publications dans: Cirugía Andaluza

Résumé

Recent advances in molecular biology and DNA sequencing have left to a more accurate classification of breast cancer which correlates better with risk of relapse and treatment response. This classification establishes four types of breast cancer: Luminal A, luminal B, HER 2 and triple-negative. Luminal A has the better prognosis, while triple-negative has the worse. The combination of histological and molecular classifications allow us to classify our patients based on their risk, which allow us to provide personalized management.

Références bibliographiques

  • Red Española de Registros de Cáncer. [último acceso el 06/03/21]. Accesible en: http://redecan.es/redecan.org/es/page3f38.html?id=21&title=estadisticas.
  • Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi: 10.1038/35021093
  • Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221.
  • Giuliano A, Edge S, HortobagyiG. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Annals of Surgical Oncology. 2018; 25(7):1783-1785.
  • Tan P, Ellis I, Allison K, Brogi E, Fox S, Lakhani S et al. The 2019 World Health Organization classification of tumours of the breast. 2020;77(2):181-185. doi: 10.1111/his.14091.
  • Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(10):1674.
  • Andrés R, Pajares I, Balmaña J, Llort G, Ramón Y Cajal T, Chirivella I, et al. Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC) Clin Transl Oncol. 2014;16(3):280–284. doi: 10.1007/s12094-013-1070-9.
  • Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res 2019; 80S: SABCS #GS3-04.
  • Garmpis N, Damaskos C, Garmpi A, Nikolettos K, Dimitroulis D, Diamantis E, et al. Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer. In Vivo. 2020 Jul-Aug;34(4):1715-1727. doi: 10.21873/invivo.11965.
  • Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015; 21:1688.
  • Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.
  • Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11(6):e0157368.
  • Woeste MR, Bhutiani N, Donaldson M, McMasters KM, Ajkay N. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery. J Surg Oncol 2021; 123:439.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018; 19:27.
  • von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796.
La source de données: Dialnet